Home › Compare › CRRTF vs ORCC
CRRTF yields 370.37% · ORCC yields 9.79%● Live data
📍 CRRTF pulled ahead of the other in Year 1
Combined, CRRTF + ORCC cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CRRTF + ORCC for your $10,000?
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Full CRRTF Calculator →Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.
Full ORCC Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.